FIELD: respiratory alleviation preparations. SUBSTANCE: composition in the form of dry powder contains pharmaceutically-active polypeptide associated with surfactant-type promoter. The latter increases absorption of polypeptide in lower respiratory pathways. Its amount represents more than 10% of the total weight of polypeptide and promoter. At least 50% of powder consists of particles with diameter lesser than or equal to 10 mcm, or agglomerates of these particles. Inhaled composition provides system transportation of therapeutically-active peptides and proteins into lungs and absorption of drugs. EFFECT: enhanced treatment efficiency. 31 cl, 3 dwg, 1 tbl, 4 ex
Authors
Dates
2000-11-20—Published
1994-06-23—Filed